With the recent launches of Novo Nordisk’s Wegovy pill and Eli Lilly’s Foundayo, the obesity market has started to shift toward oral GLP-1 drugs. While Novo leverages its first-mover advantage with ...

We independently evaluate all of our recommendations. If you click on links we provide, we may receive compensation. Will Baker is a full-time associate editor at Investopedia. He has over a decade of ...